Treatment of Poor Risk Myelodysplasia With the Combination of Amifostine, Topotecan and ARA-C: A Phase II Study
- Determine the toxic effects of amifostine, topotecan, and cytarabine in patients with
poor risk myelodysplastic syndrome.
- Determine the hematologic response rate, cytogenetic response rate, and the rate of
polyclonal hematopoiesis following this treatment regimen.
- Determine the duration of response and time to disease progression following this
treatment regimen in these patients.
OUTLINE: Patients receive topotecan by continuous IV over 24 hours plus cytarabine IV over 2
hours, on days 1-5. Patients receive amifostine IV over 15 minutes every other day for a
maximum of 60 days. Patients may receive a second course of the same regimen 8 weeks after
Patients are followed at least monthly for 2 years, then every 3-6 months until death.
PROJECTED ACCRUAL: Approximately 25 patients will be accrued for this study within 1 to 1.5
Primary Purpose: Treatment
Henry C. Fung, MD, FRCPE
Beckman Research Institute
United States: Federal Government
|Cancer Center and Beckman Research Institute, City of Hope
|Duarte, California 91010-3000